# US 2013/0210887 A1 · Dendrimers as non-viral vehicles for gene therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210887 A1
- Document ID: US20130210887A1
- Status: Published application
- Kind: A1
- Application number: 13/582,919
- Filed: 2011-03-04
- Published: 2013-08-15
- Earliest claimed: 2010-03-05
- Assignees: Universidad De Castilla La Mancha
- Inventors: Valentin Cena Callejo; Maria Del Prado Sánchez Verdu; Sonia Merino Guijarro; Joaquin Calixto García Martínez; Julián Rodríguez López; Ester Vázquez Fernández-Pacheco; María Antonia Herrero Chamorro; Ana Campo Rodrigo; Iván Rivilla De La Cruz; Francisco Carlos Pérez Martínez; Francisco Javier Guerra Navarro
- Web page: https://patentgrep.com/patent/US20130210887A1

## CPC

- C07C 233/40: having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/0033: {the non-active part being non-polymeric}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- C07C 237/10: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07H 21/02: with ribosyl as saccharide radical
- C08G 83/003: {Dendrimers}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to novel compounds of general formula (I) and (II) for their use in gene therapy as non-viral vehicles and their use for the preparation of a medicament. It also discloses the process of synthesis of said compounds of general formula (I) and (II).

## Claims

### Claim 1

A compound of general formula (I)
or a salt, prodrug or solvate thereof;
wherein:
W is selected from the group formed by any polymer or dendrimer derived from polyphenylenevinylene, polyphenyleneethylidene or hybrid of both, any conjugated organic compound that combines double bonds, triple bonds or a composition of both in its structure, any substitution with electron-donor or electro-attractor groups of the previous, any conjugated organic compound that alternates in its structure double bonds, triple bonds or a combination of both with aromatic rings of phenyl, naphthalene, phenanthrene, anthracene, pyrrole, furan, thiophene, pyridine, aromatic heterocyclic bases such as cytosine, uracil, adenine, thymine and guanine, or any substitution with electron-donor or electro-attractor groups of the previous, any non-conjugated organic compound that contains aromatic rings of phenyl, naphthalene, phenanthrene, anthracene, pyrrole, furan, thiophene, pyridine, aromatic heterocyclic bases such as cytosine, uracil, adenine, thymine and guanine, or any substitution with electron-donor or electro-attractor groups of the previous or any combination thereof;
X1, X2 and X3 are the same or different and are selected from any heteroatom,
Y is selected from a saturated or unsaturated alkyl group (C2-C12) or cycloalkyl (C3-C8), cycloalkenyl, aryl or heteroaryl,
R1 and R2 are the same or different bound to a primary, secondary or tertiary amino group and are selected from hydrogen, saturated or unsaturated alkyl (C1-C12), cycloalkyl (C3-C8), cycloalkenyl, aryl or heteroaryl,
n represents the number of branches and is a whole number selected from between 1 and 10.

### Claim 2 (depends on 1)

A compound of general formula (II) according to claim 1
or a salt, prodrug or solvate thereof;
wherein:
W is selected from the group formed by any polymer or dendrimer derived from polyphenylenevinylene, polyphenyleneethylidene or hybrid of both, any conjugated organic compound that combines double bonds, triple bonds or a composition of both in its structure, any substitution with electron-donor or electro-attractor groups of the previous, any conjugated organic compound that alternates in its structure double bonds, triple bonds or a combination of both with aromatic rings of phenyl, naphthalene, phenanthrene, anthracene, pyrrole, furan, thiophene, pyridine, aromatic heterocyclic bases such as cytosine, uracil, adenine, thymine and guanine, or any substitution with electron-donor or electro-attractor groups of the previous, any non-conjugated organic compound that contains aromatic rings of phenyl, naphthalene, phenanthrene, anthracene, pyrrole, furan, thiophene, pyridine, aromatic heterocyclic bases such as cytosine, uracil, adenine, thymine and guanine, or any substitution with electron-donor or electro-attractor groups of the previous or any combination thereof;
X1, X2 and X3 are the same or different and are selected from any heteroatom,
Y is selected from a saturated or unsaturated alkyl group (C2-C12) or cycloalkyl (C3-C8), cycloalkenyl, aryl or heteroaryl,
R1 and R2 are the same or different bound to a primary, secondary or tertiary amino group and are selected from hydrogen, saturated or unsaturated alkyl (C1-C12), cycloalkyl (C3-C8), cycloalkenyl, aryl or heteroaryl,
n represents the number of branches and is a whole number selected from between 1 and 10.

### Claim 3 (depends on 1)

The compound of general formula (I) according to claim 1, wherein they are in the form of salt and electrostatically bound to trifluoroacetate, chloride anion, DNA, RNA, siRNA, miRNA, antagomir, any drug, antibody, probe for the diagnosis of diseases by imaging techniques or any combination thereof.

### Claim 4 (depends on 1)

The compound of general formula (I) according to claim 1, wherein X1, X2 and X3 are the same or different and are selected from nitrogen or oxygen.

### Claim 5 (depends on 1)

The compound of general formula (I) according to claim 1, wherein Y is selected from:

### Claim 6 (depends on 1)

The compound of formula (I), according to claim 1, wherein R1 to R2 are the same or different and are independently selected from H, any substituted or non-substituted amine, basic amino acids, derivatives of cholesterol, folic acid, lactic acid, dexamethasone, sugars, lysosomotropic agents, nitrogenated heterocycles, polyethylene glycol-derivative hydrophilic chains, any diacrylate, any basic amino acid and the following structures:

### Claim 7 (depends on 1)

The compound of general formula (I), according to claim 1 selected from the list comprising:

### Claim 8 (depends on 1)

A pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to claim 1 together with one or more pharmaceutically acceptable excipients.

### Claim 9 (depends on 2)

A pharmaceutical composition characterized in that it comprises a compound of formula (II) according to claim 2 together with one or more pharmaceutically acceptable excipients.

### Claim 10 (depends on 8)

The composition according to claim 8, characterized in that it further comprises one or more active principles.

### Claim 11

A process of synthesis of the compounds of general formula (I), characterized in that it comprises the following stages:
wherein:
W is selected from the group formed by any polymer or dendrimer derived from polyphenylenevinylene, polyphenyleneethylidene or hybrid of both, any conjugated organic compound that combines double bonds, triple bonds or a composition of both in its structure, any substitution with electron-donor or electro-attractor groups of the previous, any conjugated organic compound that alternates in its structure double bonds, triple bonds or a combination of both with aromatic rings of phenyl, naphthalene, phenanthrene, anthracene, pyrrole, furan, thiophene, pyridine, aromatic heterocyclic bases such as cytosine, uracil, adenine, thymine and guanine, or any substitution with electron-donor or electro-attractor groups of the previous, any non-conjugated organic compound that contains aromatic rings of phenyl, naphthalene, phenanthrene, anthracene, pyrrole, furan, thiophene, pyridine, aromatic heterocyclic bases such as cytosine, uracil, adenine, thymine and guanine, or any substitution with electron-donor or electro-attractor groups of the previous or any combination thereof;
A is selected from X1, X2 and X3
X1, X2 and X3 are the same or different and are selected from any heteroatom,
Y is selected from a saturated or unsaturated alkyl group (C2-C12) or cycloalkyl (C3-C8), cycloalkenyl, aryl or heteroaryl,
R1 and R2 are the same or different bound to a primary, secondary or tertiary amino group and are selected from hydrogen, saturated or unsaturated alkyl (C1-C12), cycloalkyl (C3-C8), cycloalkenyl, aryl or heteroaryl, and
n represents the number of branches and is a whole number selected from between 1 and 10.

### Claim 12 (depends on 10)

A process for the obtainment of a compound of general formula (II), wherein it starts from the compound of general formula (I) and it repeats all steps a-c according to claim 10.

### Claim 13

(canceled)

### Claim 14 (depends on 8)

A method for prevention or treatment of pathologies selected from nervous system diseases and diseases that present the appearance of tumours, osteoporosis, diabetes, peritoneal dialysis and viral infections, including those caused by the human immunodeficiency syndrome virus (AIDS) comprising administering an effective amount of a pharmaceutical composition according to claim 8 to a subject in need thereof.

### Claim 15 (depends on 1)

A siRNA transfection kit in primary cultures of nerve cells, glia, tumoral cells, fibroblasts, osteoblasts and primary cells comprising the compound of general formula (I) according to claim 1.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

Probes for the diagnosis of diseases by imaging techniques comprising the compound of general formula (I) according to claim 1.

### Claim 18 (depends on 1)

A vehicle for the selective delivery of drugs, genetic material or cell line image probes comprising the compound of general formula (I) according to claim 1.

### Claim 19 (depends on 2)

The compound of general formula (II) according to claim 2, wherein they are in the form of salt and bound to trifluoroacetate, chloride anion, DNA, RNA, siRNA, miRNA, antagomir, any drug, antibody, probe for the diagnosis of diseases by imaging techniques or any combination thereof.

### Claim 20 (depends on 2)

The compound of general formula (II) according to claim 2, wherein X1, X2 and X3 are the same or different and are selected from nitrogen or oxygen.

### Claim 21 (depends on 2)

The compound of general formula (II) according to claim 2, wherein Y is selected from:

### Claim 22 (depends on 2)

The compound of formula (II), according to claim 2, wherein R1 to R2, are the same or different and are independently selected from H, any substituted or non-substituted amine, basic amino acids, derivatives of cholesterol, folic acid, lactic acid, dexamethasone, sugars, lysosomotropic agents, nitrogenated heterocycles, polyethylene glycol-derivative hydrophilic chains, any diacrylate, any basic amino acid and the following structures:

### Claim 23 (depends on 2)

The compound of general formula (II), according to claim 2 selected from the list comprising:

### Claim 24 (depends on 9)

The composition according to claim 9, characterized in that it further comprises one or more active principles.

### Claim 25 (depends on 9)

A method for prevention or treatment of pathologies selected from nervous system diseases and diseases that present the appearance of tumours, osteoporosis, diabetes, peritoneal dialysis and viral infections, including those caused by the human immunodeficiency syndrome virus (AIDS) comprising administering an effective amount of a pharmaceutical composition according to claim 9 to a subject in need thereof.

### Claim 26 (depends on 2)

A siRNA transfection kit in primary cultures of nerve cells, glia, tumoral cells, fibroblasts, osteoblasts and primary cells comprising the compound of general formula (II) according to claim 2.

### Claim 27 (depends on 2)

Probes for the diagnosis of diseases by imaging techniques comprising the compound of general formula (II) according to claim 2.

### Claim 28 (depends on 2)

A vehicle for the selective delivery of drugs, genetic material or cell line image probes comprising the compound of general formula (II) according to claim 2.
